Evicenter
Trodelvy (sacituzumab govitecan-hziy) in Metastatic triple-negative breast cancer
Manufacturer
Gilead Sciences, Inc.
Prescribing information
Trodelvy (opens in a new tab)
Questions
47
Last updated

All questions

Safety: Trodelvy (sacituzumab govitecan-hziy) in metastatic triple-negative breast cancer

12 questions · 4 sources

Safety

How common is neutropenia with TRODELVY?

What is the TRODELVY boxed warning for neutropenia and diarrhea?

What are the contraindications to TRODELVY?

What are TRODELVY side effects as first-line monotherapy for metastatic TNBC (ASCENT-03)?

What are TRODELVY plus pembrolizumab side effects in first-line metastatic TNBC (ASCENT-04)?

What are TRODELVY side effects in previously treated metastatic TNBC (ASCENT)?

What happens with a TRODELVY overdose?

Safety management

How is neutropenia managed with TRODELVY?

Are TRODELVY side effects more likely with reduced UGT1A1 activity?

How is diarrhea managed during TRODELVY treatment?

How are infusion reactions to TRODELVY managed?

How should TRODELVY nausea and vomiting be prevented and managed?